Piper Jaffray Expands Healthcare Equity Research with Addition of Danielle Brill and Joe Catanzaro
July 25 2018 - 10:41AM
Business Wire
Piper Jaffray Companies (NYSE: PJC), a leading investment bank
and asset management firm, is pleased to announce the hiring of
Danielle Brill and Joe Catanzaro as senior research analysts in its
healthcare equity research group. Covering the biotech sector,
Brill and Catanzaro will be based in the firm’s New York
office.
“Biopharma is core to our strategy at Piper Jaffray and these
hires demonstrate our commitment to providing our institutional and
corporate clients with the highest-quality equity research in the
industry,” said Michael Cox, co-head of global equities at Piper
Jaffray. “When combined with recent additions in sales and trading,
we now have one of the broadest biopharma equities platforms on
Wall Street.”
Brill has more than 10 years’ experience in the pharmaceutical
industry. Prior to joining Piper Jaffray, Brill was an analyst with
Needham & Company covering smid-cap biotech companies. Brill
also worked as a clinical pharmacist at Mount Sinai Hospital and
Premier Inc., and as a senior research technician at New York
University and Columbia University Medical Center. She received a
bachelor’s degree in biology from Michigan State University and
earned a doctorate of pharmacy from Ernest Mario School of Pharmacy
at Rutgers University.
Prior to joining Piper Jaffray, Catanzaro was a biotech equity
research associate at Cowen Inc., where he led the production of
Cowen’s biannual Investor’s Guide to Immuno-Oncology. Prior to
Cowen Inc., Catanzaro served as a graduate research assistant at
Stony Brook University School of Medicine and authored several
publications in peer-reviewed journals. Catanzaro received a
bachelor’s degree in biology from Binghamton University and earned
a doctorate in genetics from Stony Brook University School of
Medicine.
Piper Jaffray Companies (NYSE: PJC) is a leading investment bank
and asset management firm. Securities brokerage and investment
banking services are offered in the U.S. through Piper Jaffray
& Co., member SIPC and FINRA; in Europe through Piper Jaffray
Ltd., authorized and regulated by the U.K. Financial Conduct
Authority; and in Hong Kong through Piper Jaffray Hong Kong
Limited, authorized and regulated by the Securities and Futures
Commission. Asset management products and services are offered
through five separate investment advisory affiliates―U.S.
Securities and Exchange Commission (SEC) registered Advisory
Research, Inc., Piper Jaffray Investment Management LLC, PJC
Capital Partners LLC and Piper Jaffray & Co., and
Guernsey-based Parallel General Partners Limited, authorized and
regulated by the Guernsey Financial Services Commission.
Follow Piper Jaffray: LinkedIn | Facebook | Twitter
© 2018 Piper Jaffray Companies. 800 Nicollet Mall, Suite 1000,
Minneapolis, Minnesota 55402-7036
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180725005503/en/
Piper Jaffray CompaniesPamela Steensland,
612-303-8185pamela.k.steensland@pjc.com
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Piper Jaffray Companies (NYSE:PJC)
Historical Stock Chart
From Sep 2023 to Sep 2024